Multiple Sclerosis Centre of Catalonia (Cemcat)

Cemcat conducts research as one of its three main pillars aiming to contribute to improvements in diagnosis and treatment of multiple sclerosis (MS) and other neuroimmunological disorders.

We work in the international panels for MS diagnosis and clinical trials and we perform major projects within the EU research program as well as other large collaborative projects. We also have been involved in most clinical trials that have yielded every current agent for MS therapy. Accrued experience and critical mass soon allowed us to evolve into a reference centre with five opinion leaders that is present in many international research efforts as well as clinical and scientific forums.

Our work began twenty years ago in Vall d’Hebron Hospital when we started the first MS clinic and the first Neuroimmunology lab. Today Cemcat is an excellence centre for clinical care, research and education based on a holistic and integrated framework.

Patients trust and increase in numbers allowed for steady results through spearheading research performed by some 30 researchers. Our master database includes data from 7,000 patients and a large biological sample bank.

Even though our knowledge base has grown enormously, research challenges today continue to be many. The search for target biomarkers is a mainstay and one that Cemcat devotes the most resources to. Up-to-date, state-of-the-art technological resources and methodologies are put to this end by a talented team of nearly 70 professionals.

Our main aim is to continue to afford results and advancements that can speedily and solidly be brought from the bench to the bedside. Ever stronger collaboration and networking initiatives are paramount in attaining our objectives.

Our bottom line is our contribution to the understanding of the disease, improving on its diagnostic criteria and its treatment. We continue to add talent to our team to make this happen. Get in touch with us <talent@cem-cat.org>.

MAIN RESEARCH LINES

- Therapeutic Research in MS
- Susceptibility, diagnostic and prognostic markers in MS
- Study of the response to disease-modifying drugs
- MRI measures of neurodegeneration in MS – Clinical implications
- Research for therapeutic targets and/or therapeutic approaches

Located inside the Campus of Vall d’Hebron University Hospital in Barcelona, Spain, the purpose built premises housing the Cemcat opened in 2012. It devotes more than 2,000 sq.m. to people with multiple sclerosis.